The metabolic syndrome: time for a critical appraisal
暂无分享,去创建一个
R. Kahn | E. Ferrannini | M. Stern | J. Buse
[1] M. Laakso,et al. Cardiovascular disease risk factors as predictors of Type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects , 1993, Diabetologia.
[2] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[3] T. Lumley,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.
[4] D. Giugliano,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.
[5] T. Dinan,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.
[6] D. Cheța. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.
[7] Paul Zimmet,et al. [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. , 2005, Revista espanola de cardiologia.
[8] L. Chambless,et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. , 2005, Diabetes.
[9] Richard Kahn,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.
[10] C. Polman,et al. Effect of rimonabant on weight reduction and cardiovascular risk , 2005, The Lancet.
[11] E. Gale. The myth of the metabolic syndrome , 2005, Diabetologia.
[12] Laura M. Stapleton,et al. Re: "(Mis)use of factor analysis in the study of insulin resistance syndrome". , 2005, American journal of epidemiology.
[13] H. Kolb,et al. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. , 2005, European journal of endocrinology.
[14] K. Hunt,et al. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. , 2005, Atherosclerosis. Supplements.
[15] S. Fowler,et al. The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial , 2005, Annals of Internal Medicine.
[16] E. Lakatta,et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. , 2005, Diabetes care.
[17] Ralph D'Agostino,et al. Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors , 2005, Annals of Internal Medicine.
[18] Maria Inês Schmidt,et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.
[19] Ken Williams,et al. Identification of individuals with insulin resistance using routine clinical measurements. , 2005, Diabetes.
[20] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[21] Piero Avogaro,et al. Associazione di iperlipemia, diabete mellito e obesita' di medio grado , 1967, Acta diabetologia latina.
[22] A. H. Kadish. Cybernetics of blood sugar and fat in health and disease , 2005, Acta diabetologia latina.
[23] D. Lawlor,et al. (Mis)use of factor analysis in the study of insulin resistance syndrome. , 2005, American journal of epidemiology.
[24] S. Haffner,et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.
[25] A. Biggeri,et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. , 2004, Diabetes care.
[26] J. Tuomilehto,et al. The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a chinese population with high postprandial glucose. , 2004, Diabetes care.
[27] R. Marfella,et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.
[28] Ken Williams,et al. National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.
[29] Nathan D. Wong,et al. Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.
[30] M. Reilly,et al. Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis , 2004, Circulation.
[31] Jane B Shofer,et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. , 2004, Diabetes.
[32] M. Rutter,et al. C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.
[33] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[34] Arvind Shah,et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). , 2004, Diabetes care.
[35] John Horgan,et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. , 2004, Circulation.
[36] Paul M Ridker,et al. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.
[37] Nader Rifai,et al. Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.
[38] J. Levy,et al. Use and abuse of HOMA modeling. , 2004, Diabetes care.
[39] S. Blair,et al. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. , 2004, Archives of internal medicine.
[40] C. Lamendola,et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. , 2004, Diabetes.
[41] E. Ford. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.
[42] J. Peters,et al. Evaluating the performance of the Framingham risk equations in a population with diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[43] A. Jenkins,et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. , 2004, Diabetes care.
[44] P. M. Brown,et al. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[45] S. Reis,et al. Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women’s Ischemia Syndrome Evaluation , 2004, Circulation.
[46] S. Grundy,et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[47] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.
[48] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[49] A. Gotto,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2004, The American journal of cardiology.
[50] M. Stern,et al. The insulin resistance syndrome: the controversy is dead, long live the controversy! , 1994, Diabetologia.
[51] L. Welin,et al. Hyperinsulinaemia is not a major coronary risk factor in elderly men , 1992, Diabetologia.
[52] S. Haffner,et al. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.
[53] A. Fontbonne,et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up , 1991, Diabetologia.
[54] P. Ducimetiere,et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population , 1980, Diabetologia.
[55] T. S. Group. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies , 2004 .
[56] Lex M. Bouter,et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies , 2004, Diabetologia.
[57] K. Wellen,et al. Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.
[58] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[59] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[60] Tracey McLaughlin,et al. Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant , 2003, Annals of Internal Medicine.
[61] M. Jensen,et al. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.
[62] M. Davidson. Is treatment of insulin resistance beneficial independent of glycemia? , 2003, Diabetes care.
[63] Richard Hellman,et al. American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[64] S. Grundy,et al. The metabolic syndrome: a practical guide to origins and treatment: Part II. , 2003, Circulation.
[65] K. Nakao,et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.
[66] R. D'Agostino,et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. , 2003, Diabetes.
[67] R. Henry,et al. Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.
[68] P. Macfarlane,et al. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.
[69] S. Kihara,et al. Erratum , 2003, Heart.
[70] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[71] S. Teutsch,et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.
[72] Avron Spiro,et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. , 2003, American journal of epidemiology.
[73] J. Manson,et al. C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[74] E. Ford,et al. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. , 2003, Diabetes care.
[75] B. Howard,et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.
[76] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[77] Nancy R Cook,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.
[78] P. Ridker. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.
[79] S. Kihara,et al. Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[80] S. Teutsch,et al. THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .
[81] See S Hadid. Is Treatment of Insulin Resistance Beneficial Independent of Glycemia , 2003 .
[82] E. Ford,et al. Factor analysis and defining the metabolic syndrome. , 2003, Ethnicity & disease.
[83] S. Grundy,et al. The metabolic syndrome: practical guide to origins and treatment: Part I. , 2003, Circulation.
[84] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[85] Jukka T Salonen,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.
[86] C. Lamendola,et al. Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein , 2002, Circulation.
[87] A. Onat,et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. , 2002, Atherosclerosis.
[88] C. Zoccali,et al. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.
[89] J. Brunzell,et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. , 2002, The American journal of cardiology.
[90] P. Nilsson,et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.
[91] Ronald Klein,et al. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. , 2002, Diabetes care.
[92] Moyses Szklo,et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. , 2002, Diabetes.
[93] B. Balkau,et al. Insulin: in search of a syndrome , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[94] S. Haffner,et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.
[95] P. Savage,et al. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. , 2002, Diabetes.
[96] S. Maruoka,et al. Decreased plasma adiponectin concentrations in women with dyslipidemia. , 2002, The Journal of clinical endocrinology and metabolism.
[97] G. Yoshino,et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. , 2002, Diabetes care.
[98] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[99] Sc Prospective,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .
[100] S. Kihara,et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[101] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[102] N. Day,et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. , 2001, Diabetes care.
[103] M. Laakso,et al. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. , 2001, Diabetes care.
[104] G. Reaven,et al. Insulin resistance as a predictor of age-related diseases. , 2001, The Journal of clinical endocrinology and metabolism.
[105] K. Yeo,et al. Predicting CHD risk in patients with diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[106] T. Funahashi,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .
[107] L. Groop,et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.
[108] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[109] H. Lebovitz,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .
[110] C. Bogardus,et al. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. , 2000, Diabetes.
[111] P. Wahl,et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.
[112] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[113] S. Haffner,et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.
[114] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[115] S. Haffner,et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. , 2000, Circulation.
[116] G. Reaven,et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. , 2000, Diabetes care.
[117] S. Humphries,et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.
[118] M. Laakso,et al. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.
[119] M. Laakso,et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[120] M. Laakso,et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. , 1999, Circulation.
[121] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[122] M. Rewers,et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. , 1999, Diabetes care.
[123] S. Coppack,et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[124] S. Haffner,et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[125] M. Laakso,et al. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. , 1999, Diabetes care.
[126] P. Savage,et al. Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. , 1998, American journal of epidemiology.
[127] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[128] M. Laakso,et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 1998, Circulation.
[129] G. Reaven,et al. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. , 1998, The Journal of clinical endocrinology and metabolism.
[130] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[131] R Peto,et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.
[132] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[133] G. Riccardi,et al. Plasma Fibrinogen: A New Factor of the Metabolic Syndrome: A population-based study , 1998, Diabetes Care.
[134] P. Sweetnam,et al. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies , 1998, Heart.
[135] S. Haffner,et al. Development of the multiple metabolic syndrome: an epidemiologic perspective. , 1998, Epidemiologic reviews.
[136] Ralph B D'Agostino,et al. Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study , 1997, Diabetes.
[137] R N Bergman,et al. Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. , 1997, American journal of epidemiology.
[138] A. Folsom,et al. A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 1997, Diabetes Care.
[139] P. Whincup,et al. Serum insulin and incident coronary heart disease in middle-aged British men. , 1996, American journal of epidemiology.
[140] P. Metcalf,et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. , 1996, Metabolism: clinical and experimental.
[141] R. Bergman,et al. Insulin Sensitivity and Atherosclerosis , 1996 .
[142] B. Duncan,et al. A Metabolic Syndrome in Whites and African-Americans: The Atherosclerosis Risk in Communities baseline study , 1996, Diabetes Care.
[143] G. Dagenais,et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.
[144] K. Polonsky,et al. Report of the American Diabetes Association's Task Force on Standardization of the Insulin Assay , 1996, Diabetes.
[145] R. Bergman,et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1996, Circulation.
[146] P. McKeigue,et al. Associations Between Insulin Levels and Cardiovascular Disease Are Confounded by Comorbidity , 1995, Diabetes Care.
[147] E. Barrett-Connor,et al. Is Insulin Really a Heart Disease Risk Factor? , 1995, Diabetes Care.
[148] G. Reaven,et al. Pathophysiology of insulin resistance in human disease. , 1995, Physiological reviews.
[149] J. Jespersen,et al. Fasting Serum Insulin Levels and Coronary Heart Disease in a Danish Cohort: 17-year Follow-up , 1995, Journal of cardiovascular risk.
[150] B. Fagerberg,et al. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. , 1995, Stroke.
[151] E. Barrett-Connor,et al. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. , 1994, American journal of epidemiology.
[152] L. Kuller,et al. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. , 1994, Annals of epidemiology.
[153] Donald A. Smith. Fibrinogen as a cardiovascular risk factor: a meta-analysis , 1993, ACP Journal Club.
[154] M. Blankenstein,et al. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. , 1993, Metabolism: clinical and experimental.
[155] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[156] J. Després,et al. Abdominal obesity as important component of insulin-resistance syndrome. , 1993, Nutrition.
[157] S. Haffner,et al. Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.
[158] G. Reaven,et al. Evidence for an independent relationship between insulin resistance and fasting plasma HDL‐cholesterol, triglyceride and insulin concentrations , 1992, Journal of internal medicine.
[159] M. Laakso,et al. Asymptomatic atherosclerosis and insulin resistance. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[160] L. Niskanen,et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990, Circulation.
[161] M. Laakso,et al. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. , 1990, Arteriosclerosis.
[162] M. IUusitupa,et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990 .
[163] M. Saad,et al. Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[164] L. Wilhelmsen,et al. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. , 1989, BMJ.
[165] E. Bonora,et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. , 1989, The New England journal of medicine.
[166] R. Warnke,et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. , 1989, The New England journal of medicine.
[167] G. Reaven. Role of Insulin Resistance in Human Disease , 1988, Diabetes.
[168] R. DeFronzo. The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.
[169] S. Haffner,et al. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. , 1988, Metabolism: clinical and experimental.
[170] S. Haffner,et al. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. , 1986, Arteriosclerosis.
[171] H. Halkin,et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.
[172] L H Kuller,et al. Plasma insulin and lipoprotein concentrations: an atherogenic association? , 1983, American journal of epidemiology.
[173] J. E. Jackson,et al. Factor analysis, an applied approach , 1983 .
[174] E. Barrett-Connor,et al. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. , 1983, American journal of epidemiology.
[175] J. A. Scarlett,et al. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. , 1982, The American journal of physiology.
[176] A. Gotto,et al. Relationship of hypertriglyceridemia to atherosclerosis. , 1981, Arteriosclerosis.
[177] M. Shipley,et al. CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.
[178] T. Welborn,et al. Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations , 1979, Diabetes Care.
[179] D L McGee,et al. Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.
[180] K. Pyörälà,et al. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. , 1979, Diabetes care.
[181] H. Haller. [Epidermiology and associated risk factors of hyperlipoproteinemia]. , 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.
[182] P. Singer. [Diagnosis of primary hyperlipoproteinemias]. , 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.
[183] G. Reaven,et al. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. , 1975, The Journal of clinical investigation.
[184] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.
[185] G. Reaven,et al. Reappraisal of the role of insulin in hypertriglyceridemia. , 1974, The American journal of medicine.
[186] H. Blackburn,et al. Coronary heart disease: overweight and obesity as risk factors. , 1972, Annals of internal medicine.
[187] G. Reaven,et al. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. , 1970, The Journal of clinical investigation.
[188] G. Reaven,et al. Role of insulin in endogenous hypertriglyceridemia. , 1967, The Journal of clinical investigation.
[189] Copeman Pw,et al. THE AMERICAN AND HIS DIET. , 1964 .
[190] H. Himsworth. DIABETES MELLITUS: ITS DIFFERENTIATION INTO INSULIN-SENSITIVE AND INSULIN-INSENSITIVE TYPES , 1936 .